Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 10 de 10
Filtre
1.
Arq. neuropsiquiatr ; 75(3): 142-146, Mar. 2017. tab, graf
Article Dans Anglais | LILACS | ID: biblio-838885

Résumé

ABSTRACT The enzyme glutamic acid decarboxylase (GAD), present in GABAergic neurons and in pancreatic beta cells, catalyzes the conversion of gamma-aminobutyric acid (GABA). The cerebellum is highly susceptible to immune-mediated mechanisms, with the potentially treatable autoimmune cerebellar ataxia associated with the GAD antibody (CA-GAD-ab) being a rare, albeit increasingly detected condition. Few cases of CA-GAD-ab have been described. Methods This retrospective and descriptive study evaluated the clinical characteristics and outcomes of patients with CA-GAD-ab. Result Three patients with cerebellar ataxia, high GAD-ab titers and autoimmune endocrine disease were identified. Patients 1 and 2 had classic stiff person syndrome and insidious-onset cerebellar ataxia, while Patient 3 had pure cerebellar ataxia with subacute onset. Patients received intravenous immunoglobulin therapy with no response in Patients 1 and 3 and partial recovery in Patient 2. Conclusion CA-GAD-ab is rare and its clinical presentation may hamper diagnosis. Clinicians should be able to recognize this potentially treatable autoimmune cerebellar ataxia.


RESUMO A enzima ácido glutâmico descarboxilase (GAD), presente nos neurônios GABAérgicos e células beta do pâncreas, catalisa a conversão do ácido gama-aminobutírico (GABA). O cerebelo é altamente susceptível a mecanismos imunomediados, sendo a ataxia cerebelar associada ao anticorpo anti-GAD (CA-GAD) uma doença potencialmente tratável. Embora rara, sua frequência é crescente, com poucos casos descritos. Métodos Estudo retrospectivo e descritivo avaliando características clínicas e desfechos da CA-GAD. Resultados Três pacientes com CA-GAD, altos títulos de anti-GAD e doença endócrina autoimune foram identificados. Os pacientes 1 e 2 tinham síndrome da pessoa rígida em forma clássica e apresentação insidiosa da ataxia cerebelar, enquanto o paciente 3 tinha ataxia cerebelar pura e apresentação subaguda. Os pacientes 1 e 3 não melhoraram com imunoglobulina intravenosa e o paciente 2 teve recuperação parcial. Conclusão A CA-GAD é rara e pode ter apresentação clínica desafiadora. Os médicos devem ser capazes de reconhecer essa forma potencialmente tratável de ataxia cerebelar autoimune.


Sujets)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Autoanticorps/sang , Ataxie cérébelleuse/complications , Glutamate decarboxylase/sang , Imagerie par résonance magnétique , Ataxie cérébelleuse/diagnostic , Ataxie cérébelleuse/immunologie , Ataxie cérébelleuse/traitement médicamenteux , Études rétrospectives , Résultat thérapeutique , Immunoglobulines par voie veineuse/usage thérapeutique , Glutamate decarboxylase/immunologie
2.
Medicina (B.Aires) ; 73 Suppl 1: 49-54, 2013.
Article Dans Espagnol | LILACS, BINACIS | ID: biblio-1165148

Résumé

Autosomal recessive cerebellar ataxias belong to a broader group of disorders known as inherited ataxias. In most cases onset occurs before the age of 20. These neurological disorders are characterized by degeneration or abnormal development of the cerebellum and spinal cord. Currently, specific treatment is only available for some of the chronic ataxias, more specifically those related to a known metabolic defect, such as abetalipoproteinemia, ataxia with vitamin E deficiency, and cerebrotendinous xanthomatosis. Treatment based on a diet with reduced intake of fat, supplementation of oral vitamins E and A, and the administration of chenodeoxycholic acid could modify the course of the disease. Although for most of autosomal recessive ataxias there is no definitive treatment, iron chelators and antioxidants have been proposed to reduce the mitochondrial iron overload in Friederich’s ataxia patients. Corticosteroids have been used to reduce ataxia symptoms in ataxia telangiectasia. Coenzyme Q10 deficiency associated with ataxia may be responsive to Co Q10 or ubidecarenone supplementations. Early treatment of these disorders may be associated with a better drug response.


Sujets)
Ataxie cérébelleuse/traitement médicamenteux , Ataxie cérébelleuse/étiologie , Ataxie de Friedreich/traitement médicamenteux , Ataxie/traitement médicamenteux , Hormones corticosurrénaliennes/usage thérapeutique , Faiblesse musculaire/traitement médicamenteux , Carence en vitamine E/complications , Maladie chronique , Maladies mitochondriales/traitement médicamenteux , Humains , Protéines de liaison au fer/physiologie , Ubiquinones/déficit , Vitamine E/usage thérapeutique
3.
Medicina (B.Aires) ; 73 Suppl 1: 30-7, 2013.
Article Dans Espagnol | LILACS, BINACIS | ID: biblio-1165150

Résumé

Acute cerebellar ataxia of childhood is the most frequent neurological complication of chickenpox virus infection. Acute cerebellar ataxia is categorized within the group of acute postinfectious complications. The aims of this study were: (I) to evaluate the clinical presentation, management, and follow-up of children hospitalized due to acute cerebellar ataxia in a tertiary pediatric hospital, where immunization for chickenpox is not available, and (II) to describe the differential diagnosis of acute postinfectious cerebellitis. We evaluated 95 patients with acute cerebellar ataxia. The diagnostic criteria for acute ataxia were: Acute-onset loss of coordination or gait difficulties, with or without nystagmus, lasting less than 48 hours in a previously healthy child. All children met the inclusion criteria, except those with drug-induced ataxia in whom duration should be less than 24 hours for inclusion in the study. The data were recorded in a clinical pediatrics and neurological chart. Among immunosuppressed patients acute cerebellar ataxia was most frequently due to chickenpox. Most of the patients were male. Age at presentation ranged from preschool to 5 years of age. Time lapse between presentation of the rash and hospital admission ranged from 1 to 3 days. CSF study was performed in 59.5


of the cases. Brain magnetic resonance imaging and computed tomography scan showed edema in 33.3


. Intravenous acyclovir was used in 23 patients, however, no significant differences were found in clinical manifestations and follow-up between treated and untreated patients. Ataxia was the first clinical manifestation. Mean hospital stay ranged from 2 to 11 days with a mean of 4 days.


Sujets)
Ataxie cérébelleuse/diagnostic , Ataxie cérébelleuse/étiologie , Aciclovir/usage thérapeutique , Antiviraux/usage thérapeutique , Ataxie cérébelleuse/traitement médicamenteux , Enfant , Diagnostic différentiel , Maladie aigüe , Études rétrospectives , Facteurs temps , Femelle , Humains , Mâle
9.
Rev. chil. pediatr ; 56(2): 107-8, mar.-abr. 1985.
Article Dans Espagnol | LILACS | ID: lil-1150

Résumé

Una niña de 8 años presentó síntomas de compromiso cerebeloso al término de la primera semana de evolución de una fiebre tifoídea demostrada con hemocultivos ymielocultivos. Los exámenes y el cultivo de líquido cefalorraquídeo dieron resultados normales. Los síntomas y signos desaparecieron después de iniciar el tratamiento con Cloramfenicol y estaban ausentes quince días después del alta


Sujets)
Enfant , Humains , Femelle , Ataxie cérébelleuse/étiologie , Fièvre typhoïde/complications , Ataxie cérébelleuse/traitement médicamenteux , Chloramphénicol/usage thérapeutique
SÉLECTION CITATIONS
Détails de la recherche